Lenalidomide

BRAND NAMES

• Revlimid (most widely known and original brand; marketed by Bristol Myers Squibb) 

• Lenalid (generic-brand name used in some countries)

• Lenomid (seen in certain international markets) 

• Lenvamid (regional/generic variations in some regions)

MECHANISM OF ACTION

Lenalidomide is an immunomodulatory drug that works by binding to cereblon, a component of the E3 ubiquitin ligase complex, leading to the degradation of transcription factors IKZF1 and IKZF3. This results in reduced survival of malignant cells, especially in multiple myeloma, along with enhanced T-cell and NK-cell activity. It also has anti-angiogenic effects, helping to inhibit tumor growth.

PHARMACOKINETICS

Absorption 

Lenalidomide is rapidly absorbed after oral administration, reaching peak plasma levels within about 1–2 hours. Its absorption is high and not significantly affected by food, making it suitable for oral dosing without strict meal restrictions.

Distribution

Lenalidomide has a relatively small volume of distribution, approximately ~50–70 L in adults, indicating that it distributes mainly within total body water rather than extensively into tissues. It has low plasma protein binding (about ~30%) and does not significantly accumulate in tissues, which contributes to its predictable pharmacokinetic profile.

Metabolism

Lenalidomide undergoes minimal metabolism in the body and is not significantly affected by hepatic cytochrome P450 enzymes. Most of the drug remains unchanged, with only a small portion undergoing non-enzymatic breakdown into inactive metabolites, resulting in a low potential for drug interactions.

Elimination

Lenalidomide is mainly eliminated by the kidneys, with most of the drug excreted unchanged in urine. It has a short half-life of about 3 hours, and renal impairment requires dose adjustment to prevent accumulation.

PHARMACODYNAMICS

Lenalidomide has immunomodulatory, anti-proliferative, and anti-angiogenic effects. It works by binding to cereblon, leading to degradation of key transcription factors (IKZF1 and IKZF3), which reduces survival of malignant cells. It also enhances T-cell and NK-cell activity and inhibits tumor blood vessel formation.

ADMINISTRATION

Lenalidomide is administered orally, usually in capsule form, once daily or in defined cycles depending on the indication (e.g., multiple myeloma or MDS). It can be taken with or without food, and capsules should be swallowed whole with water without opening, breaking, or chewing. Dosing is adjusted based on the treatment regimen, patient tolerance, and renal function.

DOSAGE AND STRENGTH

Lenalidomide is available in oral capsule strengths of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg. The dosage varies depending on the indication, such as multiple myeloma or myelodysplastic syndromes, and is usually given in 21- or 28-day cycles. Dose adjustments are commonly made based on renal function, blood counts, and patient tolerance.

DRUG INTERACTIONS

Lenalidomide has minimal drug interactions because it is not metabolized by CYP enzymes. However, it can increase the risk of bone marrow suppression when used with other myelosuppressive drugs. Caution is also needed with agents affecting renal function, as they may alter its elimination.

FOOD INTERACTIONS

Lenalidomide has no clinically significant food interactions. It can be taken with or without food, as meals do not meaningfully affect its absorption or overall exposure. However, taking it consistently in the same way each day is recommended to maintain routine and adherence.

CONTRAINDICATIONS

Lenalidomide is contraindicated in patients with known hypersensitivity to the drug or its components. It is also strictly contraindicated in pregnancy due to its high risk of severe teratogenic effects. Use requires enrollment in a pregnancy prevention program, and it should not be used in individuals who cannot comply with required safety monitoring measures.

SIDE EFFECTS

• Neutropenia

• Thrombocytopenia

• Anemia

• Fatigue

• Diarrhea

• Rash

• Pruritus

• Venous thromboembolism

• Infections

• Secondary malignancies

• Severe skin reactions

OVER DOSE

• Severe myelosuppression 

• Neutropenia 

• Thrombocytopenia 

• Anemia 

• Fatigue and weakness 

• Increased infection risk 

• Bleeding risk 

• Supportive treatment only 

TOXICITY

Lenalidomide toxicity mainly includes bone marrow suppression (neutropenia, thrombocytopenia, anemia), increased infection risk, and venous thromboembolism. It is also highly teratogenic and can cause rare severe skin reactions.